Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Sandhoff disease is a severe neurodegenerative glycosphingolipid (GSL) lysosomal storage disorder, currently without treatment options. One therapeutic approach under investigation is substrate reduction therapy (SRT). By partially inhibiting GSL biosynthesis, the impaired rate of GSL catabolism is...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Andersson, U, Smith, D, Jeyakumar, M, Butters, T, Borja, M, Dwek, R, Platt, F
التنسيق:	Journal article
اللغة:	English
منشور في:	2004

مواد مشابهة

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
حسب: Ulrika Andersson, وآخرون
منشور في: (2004-08-01)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
حسب: Jeyakumar, M, وآخرون
منشور في: (2004)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
حسب: Andersson, U, وآخرون
منشور في: (2000)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
حسب: Baek, R, وآخرون
منشور في: (2004)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
حسب: Baek, R, وآخرون
منشور في: (2008)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
حسب: Platt, F, وآخرون
منشور في: (2003)

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
حسب: Jeyakumar, M, وآخرون
منشور في: (2001)

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
حسب: Kasperzyk, J, وآخرون
منشور في: (2004)

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
حسب: Kasperzyk, J, وآخرون
منشور في: (2004)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
حسب: Baek, R, وآخرون
منشور في: (2005)

MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.
حسب: Lowe, J, وآخرون
منشور في: (2005)

Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat
حسب: Lachmann, R, وآخرون
منشور في: (2006)

Analysis of stored oligosaccharides in a mouse model of a glycolipid storage (Sandhoff) disease
حسب: Awan, F, وآخرون
منشور في: (2003)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
حسب: Elliot-Smith, E, وآخرون
منشور في: (2008)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
حسب: Pelled, D, وآخرون
منشور في: (2003)

Beneficial effects of acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff disease
حسب: Kaya, E, وآخرون
منشور في: (2020)

New developments in treating glycosphingolipid storage diseases.
حسب: Platt, F, وآخرون
منشور في: (2005)

Substrate reduction therapy
حسب: Platt, F, وآخرون
منشور في: (2007)

Substrate reduction therapy.
حسب: Platt, F, وآخرون
منشور في: (2008)

Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
حسب: Rountree, J, وآخرون
منشور في: (2009)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
حسب: Denny, C, وآخرون
منشور في: (2010)

Infantile Sandhoff's disease
حسب: K Sass, وآخرون
منشور في: (2009-08-01)

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
حسب: Jeyakumar, M, وآخرون
منشور في: (2002)

Storage solutions: treating lysosomal disorders of the brain.
حسب: Jeyakumar, M, وآخرون
منشور في: (2005)

An inducible mouse model of late onset Tay-Sachs disease.
حسب: Jeyakumar, M, وآخرون
منشور في: (2002)

Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease.
حسب: Richardson, K, وآخرون
منشور في: (2016)

Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model
حسب: Evan Woodley, وآخرون
منشور في: (2019-03-01)

Dysregulation of the NLRP3 Inflammasome and Promotion of Disease by IL-1β in a Murine Model of Sandhoff Disease
حسب: Nick Platt, وآخرون
منشور في: (2025-01-01)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
حسب: te Vruchte, D, وآخرون
منشور في: (2010)

An Inducible Mouse Model of Late Onset Tay–Sachs Disease
حسب: Mylvaganam Jeyakumar, وآخرون
منشور في: (2002-08-01)

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
حسب: Andersson, U, وآخرون
منشور في: (2004)

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
حسب: Platt, F, وآخرون
منشور في: (2001)

Pharmacological impairment of acrosome formation and sperm head morphogenesis reveals essential role of glycosphingolipids in spermiogenesis
حسب: van der Spoel, A, وآخرون
منشور في: (2002)

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
حسب: Karen M Ashe, وآخرون
منشور في: (2011-01-01)

Decrease in Myelin-Associated Lipids Precedes Neuronal Loss and Glial Activation in the CNS of the Sandhoff Mouse as Determined by Metabolomics
حسب: Emmanuelle Lecommandeur, وآخرون
منشور في: (2020-12-01)

Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation.
حسب: Mellor, H, وآخرون
منشور في: (2003)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
حسب: Jeyakumar, M, وآخرون
منشور في: (2003)

Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of Sandhoff disease.
حسب: Yasuhiro Ogawa, وآخرون
منشور في: (2013-01-01)

Abnormal differentiation of Sandhoff disease model mouse-derived multipotent stem cells toward a neural lineage.
حسب: Yasuhiro Ogawa, وآخرون
منشور في: (2017-01-01)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
حسب: Priestman, D, وآخرون
منشور في: (2008)